Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy.

The use of rifaximin significantly reduces infections in patients with cirrhosis and HE. Despite rifaximin was associated with a decreased all-cause mortality, this impact was not statistically significant in the adjusted analysis.